CYCN

Cyclerion Therapeutics (CYCN)

Cyclerion Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CYCN

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/08	05 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2024/01/27	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/12/12	07 : 09	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/12/08	06 : 05	Edgar (US Regulatory)	Form 3/A - Initial statement of beneficial ownership of securities: [Amend]	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/12/05	07 : 09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/12/05	06 : 05	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/12/04	22 : 00	GlobeNewswire Inc.	Cyclerion Appoints Regina Graul, Ph.D., as President	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/12/01	22 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/12/01	08 : 16	GlobeNewswire Inc.	Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/11/25	03 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/11/14	06 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/10/24	05 : 58	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/07/31	20 : 00	GlobeNewswire Inc.	Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/07/29	05 : 48	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/07/20	06 : 27	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/07/13	05 : 12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/06/21	05 : 56	Edgar (US Regulatory)	Proxy Statement - Merger or Acquisition (definitive) (defm14a)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/06/10	06 : 24	Edgar (US Regulatory)	Proxy Statement - Merger or Acquisition (preliminary) (prem14a)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/06/02	05 : 08	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/06/02	05 : 00	GlobeNewswire Inc.	Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/05/26	05 : 06	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/05/24	05 : 00	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/05/16	06 : 16	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/05/16	02 : 00	GlobeNewswire Inc.	Cyclerion Announces Reverse Stock Split	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/05/12	21 : 40	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/05/12	19 : 05	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/05/12	07 : 00	GlobeNewswire Inc.	Cyclerion Announces Definitive Agreement for Zagociguat and CY3018	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/05/12	07 : 00	GlobeNewswire Inc.	Cyclerion Announces Corporate Updates and Q1 2023 Financial Results	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/04/03	22 : 54	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:CYCN	Cyclerion Therapeutics Inc
2023/04/03	20 : 31	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:CYCN	Cyclerion Therapeutics Inc